81864-31-5

Upstream product

• 54186-71-9 2,2-dimethyl-5,6-nitro[1,3]benzodioxole 
• 81864-30-4 N-(2,2-dimethyl-6-nitro-benzo[1,3]dioxol-5-yl)-acetamide 
• 64-17-5 ethanol 
• 81864-29-1 N-(2,2-dimethylbenzo[1,3]dioxol-5-yl)acetamide 
• 14005-14-2 2,2-dimethyl-1,3-benzodioxole 
• 54186-68-4 2,2-dimethyl-5-nitro-1,3-benzodioxole 
• 120-80-9 benzene-1,2-diol 

Relevant academic research and scientific papers

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.